Mark Earl Hensley, Chief Operating Officer of Heron Therapeutics, Inc. /DE/ (NASDAQ:HRTX), filed a Form 4 on November 3, 2026, reporting a restricted stock unit vesting and a related tax-withholding disposition of common stock on October 30, 2026.

Key Highlights

  • RSU vesting: 11,770 restricted stock units converted to common stock on October 30, 2026, via transaction code M.
  • Shares withheld for taxes: 3,349 shares were disposed of at $0.28 per share on October 30, 2026, via transaction code F.
  • Beneficial ownership after transactions: Hensley directly holds 179,322 shares of common stock following the reported transactions.
  • Original RSU grant: The 11,770 units vested from a January 30, 2026 grant of 188,315 RSUs, which vest in 16 equal quarterly installments beginning one quarter after the grant date.
  • Remaining derivative securities: Hensley beneficially owns 153,006 RSUs following the reported transaction.

Heron Therapeutics COO Hensley Reports Quarterly RSU Vest and Tax Withholding

According to the Form 4 filed with the SEC on November 3, 2026, Mark Earl Hensley, Chief Operating Officer of Heron Therapeutics, Inc. /DE/ (NASDAQ:HRTX), reported two transactions in common stock occurring on October 30, 2026. The first was an acquisition of 11,770 shares through the vesting of restricted stock units, recorded under transaction code M. Each restricted stock unit, as the filing notes, "represents a contingent right to receive one share of common stock."

The second transaction was a disposition of 3,349 shares at a price of $0.28 per share, recorded under transaction code F, which the filing indicates is a payment of taxes in connection with the vesting event. Following both transactions, Hensley directly owned 179,322 shares of common stock, according to the filing.

The filing further discloses that the 11,770 RSUs originated from a grant made on January 30, 2026, consisting of 188,315 RSUs in total. Those RSUs vest in 16 equal quarterly installments beginning one quarter after the January 30, 2026 grant date, the filing states. After the vesting of 11,770 units, Hensley's remaining RSU position is reported as 153,006 units. The Form 4 was signed by Kathryn Lester as attorney-in-fact for Mark E. Hensley and filed on November 3, 2026.

What Was Disclosed

Heron Therapeutics COO Mark Earl Hensley disclosed the vesting of 11,770 RSUs and the withholding of 3,349 shares at $0.28 each for tax purposes on October 30, 2026, resulting in direct ownership of 179,322 shares of common stock and 153,006 remaining RSUs.